Oncoinvent ASA: Grant of share options – mandatory notification of trade
Oslo, Norway, 22 December 2025: Oncoinvent ASA (“Oncoinvent” or the “Company”) (OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announce that the Board of Directors has granted options to employees.
As previously communicated and with the objective of aligning share option participants’ interests with those of the shareholders of the Combined Company, the Board of Directors has established a replacement share option and RSU program for employees and board members similar to Oncoinvent’s program before the merger with BerGenBio. This has been transformed by using the exchange ratio in the merger and adjusting the strike to secure a value neutral transition. Following this, a total of 6,355,096 share options has been granted as replacement for the previous option program, of which 4,451,133 to primary insiders. See the attached forms.
Options granted under the share option program will normally vest equally over a four-year period from the date of grant and each option, when exercised, will give the right to receive one share in the Company at a fixed strike price set at time of grant. Options granted under the share option program expire seven years after grant date.
In addition, a total of 25,770,000 new share options were granted, equal to 5.4% of fully diluted shares in the Company. Total options outstanding after this grant are 32,125,096, equal to 6.7% of fully diluted shares in the Company. The strike price for this grant is NOK 0.50 per option equal to the volume weighted average share price the last day before the grant, limited to nominal value of the shares. Of the total grant, 15,500,000 share options were granted to primary insiders of the Company (total holdings of share options following this grant and replacement program):
Øystein Soug – CEO: 5,000,000 (6,106,466)
Kari Myren – CMO: 2,000,000 (2,358,399)
Anne-Kirsti Aksnes – CCO: 2,000,000 (2,336,751)
Gro Hjellum – COO: 2,000,000 (2,334,826)
Kristine Lofthus – CPO: 1,500,000 (1,829,534)
Stian Brekke – Head of RA: 1,500,000 (1,828,813)
Anne Cecilie Alvik – Head of QA: 1,500,000 (1,828,452)
Share options issued to the board as part of the replacement option program following the merger:
Gillies O’Bryan-Tear (Chairperson of the Board): 353,722
Kari Grønås (Board member): 165,168
Hilde Steineger (Board member): 165,168
Orlando Oliveira (Board member): 165,168
Johan Häggblad (Board member): 95,012
The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers.
PDMR notifications of transactions: replacement options
PDMR notifications of transactions: new grants
This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
